{"id":79401,"date":"2026-09-08T12:24:46","date_gmt":"2026-09-08T04:24:46","guid":{"rendered":"https:\/\/flcube.com\/?p=79401"},"modified":"2026-09-08T12:24:47","modified_gmt":"2026-09-08T04:24:47","slug":"guangdong-taienkang-completes-capital-increase-in-procapzoom-secures-exclusive-china-rights-to-world-first-ocular-surface-cell-therapy-sz018","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=79401","title":{"rendered":"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Guangdong Taienkang Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/301263:SHE\">SHE: 301263<\/a>) announced on <strong>September 8, 2026<\/strong> the completion of its <strong>capital increase in Procapzoom<\/strong>, alongside the signing of a <strong>strategic cooperation agreement<\/strong> with the company. Upon closing of the transaction, Taienkang secured the <strong>exclusive commercial promotion service rights<\/strong> for <strong>SZ018 (MSCohiO Lens Project)<\/strong> \u2014 billed as the <strong>world\u2011first ocular surface cell therapy<\/strong> \u2014 in the <strong>China region<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-deal-milestone\" class=\"wp-block-heading\">Deal Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer \/ Partner<\/strong><\/td><td>Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263)<\/td><\/tr><tr><td><strong>Counterparty<\/strong><\/td><td>Procapzoom<\/td><\/tr><tr><td><strong>Transaction Type<\/strong><\/td><td>Capital increase + strategic cooperation agreement<\/td><\/tr><tr><td><strong>Key Right Obtained<\/strong><\/td><td>Exclusive commercial promotion service rights for SZ018 in China<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SZ018 (MSCohiO Lens Project), Category 1 therapeutic biologic<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>8 Sep 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Joint advancement of commercialization in severe ocular surface cell therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Classification:<\/strong> <strong>Category 1 therapeutic biological product<\/strong> (China)<\/li>\n\n\n\n<li><strong>Modality:<\/strong> <strong>Umbilical cord\u2011derived mesenchymal stem cells (MSCs)<\/strong> delivered via a <strong>silicone hydrogel carrier<\/strong> that enables stable retention of the cells on the ocular surface<\/li>\n\n\n\n<li><strong>Safety Engineering:<\/strong> Cells undergo <strong>specialized processing to eliminate tumorigenic risk<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Potentially overcomes <strong>existing treatment bottlenecks in immune\u2011related ophthalmic diseases<\/strong>, positioning SZ018 as a first\u2011of\u2011its\u2011kind approach in ocular surface cell therapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-status\" class=\"wp-block-heading\">Regulatory Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Designation<\/strong><\/td><td><strong>FDA Orphan Drug Designation (ODD)<\/strong><\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic ocular <strong>graft\u2011versus\u2011host disease (coGVHD)<\/strong><\/td><\/tr><tr><td><strong>Granted<\/strong><\/td><td><strong>May 2023<\/strong><\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>U.S. regulatory recognition supporting development for a rare, sight\u2011threatening complication of allogeneic stem cell transplantation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Ophthalmology Landscape:<\/strong> Immune\u2011related ocular surface diseases \u2014 including severe dry eye and ocular coGVHD \u2014 remain poorly served by existing therapies, creating demand for regenerative biologics.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> The exclusive China commercialization rights extend Taienkang&#8217;s portfolio into <strong>advanced cell therapy<\/strong>, diversifying beyond its traditional pharmaceutical base.<\/li>\n\n\n\n<li><strong>Commercialization Path:<\/strong> The partnership structure pairs Procapzoom&#8217;s development assets with Taienkang&#8217;s commercial infrastructure, a common route to accelerate market entry for Category 1 biologics in China.<\/li>\n\n\n\n<li><strong>Global Validation:<\/strong> The <strong>FDA Orphan Drug Designation<\/strong> provides regulatory credibility that may support future overseas licensing and partnership opportunities.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding transaction completion, commercialization timelines, and regulatory development of SZ018. Actual results may differ due to risks including clinical trial outcomes, regulatory approval conditions, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":79402,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,4908],"tags":[44,2833,2832],"class_list":["post-79401","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-pic","tag-ophthalmology","tag-she-301263","tag-taienkang-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of its capital increase in Procapzoom, alongside the signing of a strategic cooperation agreement with the company. Upon closing of the transaction, Taienkang secured the exclusive commercial promotion service rights for SZ018 (MSCohiO Lens Project) \u2014 billed as the world\u2011first ocular surface cell therapy \u2014 in the China region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=79401\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018\" \/>\n<meta property=\"og:description\" content=\"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of its capital increase in Procapzoom, alongside the signing of a strategic cooperation agreement with the company. Upon closing of the transaction, Taienkang secured the exclusive commercial promotion service rights for SZ018 (MSCohiO Lens Project) \u2014 billed as the world\u2011first ocular surface cell therapy \u2014 in the China region.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=79401\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T04:24:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-08T04:24:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018\",\"datePublished\":\"2026-09-08T04:24:46+00:00\",\"dateModified\":\"2026-09-08T04:24:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401\"},\"wordCount\":383,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0801.webp\",\"keywords\":[\"Ophthalmology\",\"SHE: 301263\",\"Taienkang Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=79401#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=79401\",\"name\":\"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0801.webp\",\"datePublished\":\"2026-09-08T04:24:46+00:00\",\"dateModified\":\"2026-09-08T04:24:47+00:00\",\"description\":\"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of its capital increase in Procapzoom, alongside the signing of a strategic cooperation agreement with the company. Upon closing of the transaction, Taienkang secured the exclusive commercial promotion service rights for SZ018 (MSCohiO Lens Project) \u2014 billed as the world\u2011first ocular surface cell therapy \u2014 in the China region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=79401\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0801.webp\",\"width\":1080,\"height\":608,\"caption\":\"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=79401#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018 - Insight, China&#039;s Pharmaceutical Industry","description":"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of its capital increase in Procapzoom, alongside the signing of a strategic cooperation agreement with the company. Upon closing of the transaction, Taienkang secured the exclusive commercial promotion service rights for SZ018 (MSCohiO Lens Project) \u2014 billed as the world\u2011first ocular surface cell therapy \u2014 in the China region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=79401","og_locale":"en_US","og_type":"article","og_title":"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018","og_description":"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of its capital increase in Procapzoom, alongside the signing of a strategic cooperation agreement with the company. Upon closing of the transaction, Taienkang secured the exclusive commercial promotion service rights for SZ018 (MSCohiO Lens Project) \u2014 billed as the world\u2011first ocular surface cell therapy \u2014 in the China region.","og_url":"https:\/\/flcube.com\/?p=79401","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-08T04:24:46+00:00","article_modified_time":"2026-09-08T04:24:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=79401#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=79401"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018","datePublished":"2026-09-08T04:24:46+00:00","dateModified":"2026-09-08T04:24:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=79401"},"wordCount":383,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=79401#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0801.webp","keywords":["Ophthalmology","SHE: 301263","Taienkang Pharmaceutical"],"articleSection":["Company","Deals","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=79401#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=79401","url":"https:\/\/flcube.com\/?p=79401","name":"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=79401#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=79401#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0801.webp","datePublished":"2026-09-08T04:24:46+00:00","dateModified":"2026-09-08T04:24:47+00:00","description":"Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of its capital increase in Procapzoom, alongside the signing of a strategic cooperation agreement with the company. Upon closing of the transaction, Taienkang secured the exclusive commercial promotion service rights for SZ018 (MSCohiO Lens Project) \u2014 billed as the world\u2011first ocular surface cell therapy \u2014 in the China region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=79401#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=79401"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=79401#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0801.webp","width":1080,"height":608,"caption":"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=79401#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Guangdong Taienkang Completes Capital Increase in Procapzoom \u2013 Secures Exclusive China Rights to World\u2011First Ocular Surface Cell Therapy SZ018"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0801.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=79401"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79401\/revisions"}],"predecessor-version":[{"id":79403,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/79401\/revisions\/79403"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/79402"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=79401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=79401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=79401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}